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Recent advance in high-throughput sequencing technologies unexpectedly revealed that somatic 
mutations of splicing factor genes frequently occurred in several types of hematological 
malignancies including myelodysplastic syndromes (MDS) and other myeloid neoplasms and 
chronic lymphocytic leukemia (CLL).  Spicing factor mutations have been also reported in solid 
cancers such as breast cancer, pancreatic cancer, uveal melanoma and lung adenocarcinoma. 
These mutations were heterozygous and mainly affected U2AF1 (U2AF35), SRSF2 (SC35), 
SF3B1 (SF3B155 or SAP155) and ZRSR2 (URP), which are engaged in the initial steps of RNA 
splicing including 3’ splice site recognition, and occurred in a largely mutually exclusive pattern, 
suggesting a common impact of these mutations on RNA splicing. Here we describe splicing 
factor mutations reported in various types of cancers, their functional/biological effect and their 
potential as therapeutic targets. 
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RNA splicing is the process of generating a mature mRNA (messenger RNA) from pre-mRNA 
during which exon-intron borders are recognized and the intervening intronic sequences are 
removed.[1] RNA splicing enables production of multiple different mRNA species by alternative 
splicing of exons or exon segments, which are found in nearly 95% of mammalian genes to 
generate tissue- and species- specific differentiation patterns.[2] RNA splicing is catalyzed by the 
spliceosome, which is composed of five small nuclear ribonucloproteins (snRNPs) and a large 
number of auxiliary proteins.[1] On the other hand, there are two types of introns, termed U2 and 
U12 type; U2-type introns account for more than 99.5% of introns, whereas U12-type introns 
constitute less than 0.5% of introns and reside in 700-800 genes. These introns are spliced by 
the U2-type and U12-type dependent spliceosomes, which are referred to as ‘major’ and ‘minor’ 
spliceosomes, respectively.[3] The U1, U2, U4/U6, U5 snRNPs are the main components of the 
major spliceosomes and each snRNP consists of a small nuclear RNA (snRNA) and a varying 
number of associated proteins.  Catalytic process of pre-mRNA splicing is a two-step process, 
during which splicesomes are assembled in a stepwise fashion as splicing proceeds.[1, 2] In the 
first step, the 5' splice site is cleaved and, in a coordinated reaction, the 5' G residue of the intron 
is linked to an A residue near the 3' splice junction. In the second step, the 3' splice site is cleaved, 
producing ligated exons and excised "lariat" introns (Figure 1).  
Recently, several lines of evidence suggest that RNA splicing is also associated with 
transcription and splicing factors also play an important role in the transcriptional regulation[2], 
although transcription from DNA to pre-mRNA and pre-mRNA splicing were previously considered 
as separated processes. For example, splicing factor SC35 (SRSF2) has been shown to affect 
transcriptional elongation in a gene specific manner.[4] In addition, close interactions between the 
alternative splicing mechanism and chromatin modifications also has been suggested.[2]  
One of the recent, rather unexpected, findings in cancer genetics using high-throughput 
sequencing is frequent mutations of splicing factor genes found in myeloid dysplasias and to a 
lesser extent, in other hematopoietic neoplasms and solid cancers.[5-7] Among major targets of 
these mutations are U2AF1 (U2AF35), SRSF2 (SC35), SF3B1 (SF3B155 or SAP155) and ZRSR2 
(URP), which are known to be commonly involved in in the initial steps of RNA splicing. This 
review summarizes the splicing factor mutations in various types of cancers and discusses the 
mechanisms by which these mutations lead to carcinogenesis and their potential as therapeutic 
targets. 
 
RNA splicing and disease 
  
Alterations in RNA splicing have been implicated in various types of human diseases through 
disruption of either cis-acting elements within affected genes or trans-acting factors that are 
required for normal splicing or splicing regulation.[8] In general, disruption of cis-acting elements 
affects only a single gene, whereas defects in trans-acting factors could impact on multiple genes. 
Disruption of cis-acting elements is a well-known mechanism causing abnormal translation of 
protein; as many as 50% of disease-causing mutations are estimated to be cis-acting mutations 
that affect RNA splicing, leading to altered protein translation.[9] Other alterations of trans-acting 
elements, in which germline mutations affect major spliceosome components, including four 
components of U4/U5/U6 tri-snRNP complex, PRPF31, PRPF8, PRPF3 and RP9, have been 
recognized as the causes of autosomal dominant forms of retinitis pigmentosa.[10] Germline 
mutations of SF3B4, a component of U2 snRNP, have been shown to be the cause of Nager 
syndrome.[11] More recently, mutation of the minor spliceosome component, RNU4ATAC, which 
codes U4atac snRNA, is also reported as a cause of MOPD I (Taybi-Linder syndrome).[12, 13] 
Therefore mutations in ubiquitous spliceosome components actually cause only tissue-specific 
phenotypes. This cell type specificity is likely to result from sensitivitiy of some cell-specific pre-
mRNAs to dysfunction of each spliceosome component.[8, 10] For example, pre-mRNA of RDS 
and FSCN2, whose expression are specific to photoreceptor, were shown to be sensitive to 
PRPF31 mutations.[14] 
 
RNA splicing and cancer 
Deregulated or abnormal RNA splicing has been considered as a common finding in cancer cells 
and causally related to carcinogenesis[15], although a more recent analysis revealed that the 
prevalence of alternatively spliced genes was actually slightly lower in tumors compared to normal 
tissues.[16] For example, a variety of cancer cell types show increased expression of the longer, 
anti-apoptotic splicing form of the Bcl-x gene, while another shorter isoform (Bcl-x(s)) promotes 
apoptosis.[15],[17] Caspase-2 also generates both proapoptotic (caspase-2L) and anti-apoptotic 
isoforms (caspase-2S) by alternative splicing.[18] Similarly, short isoform of Fas (sFas) also have 
been shown to be antiapoptotic and elevated production of that has been observed in various 
types of cancers.[19] Although the molecular mechanism of these abnormal splicing is largely 
unknown, a recent report suggests a possible role of deregulated trans-acting factor. A member 
of the SR protein family, SRSF1 (SF2/ASF), is involved in RNA splicing and highly expressed in 
various types of human cancers, where an oncogenic role of the protein was indicated by 
transformation of SRSF1-overexpressed fibroblasts, although no oncogenic SRSF1 mutation has 
been thus far reported.[20] SRSF1 is also shown to control alternative splicing of tumor 
  
suppressor BIN1, MNK1 and S6K1 kinases, which could contribute to the oncogenic action of 
SRSF1. However, more direct evidence suggesting oncogenic role of trans-acting splicing factors 
has been obtained through comprehensive analysis of somatic mutations in a variety of cancer 
types using massively parallel sequencing, in which multiple components of the RNA splicing 
machinery were shown to be recurrently mutated. 
 
Splicing factor mutations in hematological malignancies 
MDS and related disorders are a heterogeneous group of myeloid neoplasms characterized by 
varying degrees of cytopenia and transition to acute myeloid leukemia (AML).[21] Recently, 
several groups identified frequent somatic mutations of the RNA splicing machinery in MDS using 
whole exome/genome sequencing.[22-25] Mutations are heterozygous and highly frequent (45%-
85%) in and specific to MDS and related myeloid neoplasms with myelodysplastic features, but 
less common (10%) in patients with de novo AML[22, 26] and myeloproliferative neoplasms 
(MPN) [22, 27] (Table 1) and rarely found in pediatric myeloid malignancies[28, 29] and lymphoid 
neoplasms[30] except for chronic lymphocytic leukemia (CLL).[31-33] Although more than 30 
splicing factors are known to be mutated in at least one patient[22, 26, 32, 34, 35] (Table 1), 4 
genes represent the major mutational targets, including U2AF1, SRSF2, SF3B1 and ZRSR2. 
Most of the mutations affected the components that are involved in the initial steps of pre-mRNA 
splicing including 3’-splice site recognition and occurred in a mutually exclusive manner, 
suggesting a common impact of these mutations on RNA splicing in the pathogenesis of 
myelodysplasia (Figure 2). Another conspicuous feature of spliceosome mutations is the 
presence of mutational hot spots in U2AF1, SRSF2 and SF3B1 and the lack of 
nonsense/frameshift changes, indicating that functional consequence of these mutations should 
not be a simple loss-of-function, but accompanies some gain-of-function. As mentioned below, 
however, the frequency of mutations differs significantly across disease types; SF3B1 mutations 
are extremely frequent in those MDS phenotypes showing ring sideroblasts compared to other 
MDS subtypes, while SRSF2 mutations are more common in chronic myelomonocytic leukemia 
(CMML) (28-47%). Thus, despite common association of different splicing factor mutations to 
MDS phenotypes, the functional/biological impact of each mutation may not be completely 
identical, but probably reflecting discrete function of each spliceosome component, critically 
different, which might contribute to associated disease phenotypes. SF3B1 mutations were also 
reported in 9.7-15% of CLL cases[31-33], in which these mutations tend to represent subclonal 
mutations and were significantly associated with poor clinical outcome.[36] The functional basis 
  
for the common SF3B1 mutations in chronic myeloid neoplasms and lymphoid malignancies is 
still unknown but this may indicate a possibility of the common origin of these malignancies.  
 
Mutated spliceosome components 
U2AF1 
U2AF1 (U2AF35: 35 kDa subunit of U2AF) is tightly bound to U2AF2 (U2AF65: 65 kDa subunit 
of U2AF), consisting of the U2 auxilliary factor (U2AF) heterodimer.[1] U2AF1 interacts with the 
AG dinucleotide of the 3’ splice site through its RNA recognition motif (RRM) and also play a role 
in juxtaposing the 5’ and 3’ splice sites by binding to SR proteins such as SRSF2 through its 
arginine-serine-rich (RS) domain. In addition, the pre-mRNA branch site and polypyrimidine tract 
(Py-tract) are bound by SF1/BBP and U2AF2, respectively and these interactions yield the 
spliceosomal E complex and play crucial roles in the recognition of the 3’ splice site of an intron. 
U2AF1 is mutated in 5-16% of MDS and 5-17% of CMML. More recently, recurrent U2AF1 
mutations have been reported in hairy-cell leukemia-variant (HCVv).[37] Most of reported U2AF1 
mutations were observed at two amino acid positions, S34 and Q157, which are located within 
evolutionally conserved zinc finger domains (Figure 3).[22]  
SRSF2 
SRSF2 (SC35) is a member of the SR protein family of proteins and thought to interact with exonic 
splicing enhancers (ESEs) thorough its RRM domain and recruits U2AF to the upstream 3’ splice 
site and U1 snRNP to the downstream 5’ splice site, giving positive effects on splice-site 
usage.[38] SRSF2 mutations were more frequent in CMML (28-47%). Most of reported mutations 
or insertion-deletions of SRSF2 exclusively involved P95 within the intervening sequence 
between the RRM and RS domains, indicating the gain-of-function nature of these mutations 
(Figure 3).[22] SRSF2 mutations are also reported in other myeloid malignancies including MPN 
transformed to secondary AML[39] and systemic mastocytosis.[40] 
SF3B1 (SF3b155) 
SF3B1 is a component of the SF3B complex, which consists of U2 snRNP together with the SF3A 
complex. U2 snRNP bind to a branch point sequence (BPS) via SF3B14 (p14) and also to U2AF2 
via SF3B1 (SF3b155) to stabilize the interaction between the U2 snRNA and pre-mRNA’s BPS, 
leading to the establishment of the spliceosomal A complex.[1] Although SF3B1 mutations are 
found in a variety of myeloid malignancies, extremely high mutation rates have been reported in 
those MDS subtypes showing increased ring sideroblasts (>15% of all erythroblasts in bone 
marrow), including refractory anemia with ring sideroblasts (RARS) (64-83%) and refractory 
cytopenia with multilineage dysplasia and ring sideroblasts (RCMD-RS) (37-76%).[22, 25, 41, 42] 
  
SF3B1 mutations were also common in RARS associated with marked thrombocytosis (RARS-T) 
(67-85%)[25, 41, 43], which has been classified as a unique form of 
myelodysplastic/myeloproliferative neoplasms (MDS/MPN) showing increased ring sideroblasts 
and an elevated platelet count. Moreover, even in other MDS subtypes, SF3B1 mutations were 
associated with significant increased, although less than 15%, ring sideroblasts, in which the 
presence of SF3B1 mutations showed very high positive and negative predictive values (~97.7% 
and 98.7%, respectively) for the presence of ring sideroblasts.[41] SF3B1 mutations clustered in 
several hot spots, such as K700, E622, R625, H662 and K666, located in HEAT domains that 
extend through exon12 to 15 (Figure 3).[22, 23]  
ZRSR (URP) 
ZRSR2 functions at 3’ splice site of both U2- and U12-type introns[44] and participates in the 
formation of the splicing A complex on 3’ splice sites recognition. In addition, ZRSR2 is also 
engaged in the second step of splicing at U2-type intron.[44] ZRSR2 mutations were widely 
distributed along the entire coding region and most of them were nonsense mutations or 
frameshift changes, or involved splicing donor/acceptor sites that caused either a premature 
truncation or a large structural change of the protein, leading to loss-of-function (Figure 3).[22] 
ZRSR2 mutations are less frequent in MDS compared to mutations of U2AF1, SRSF2, and SF3B1, 
and were associated with refractory anemia with excess blast (RAEB) and the international 
prognostic scoring system (IPSS) int-1 or int-2 risk-groups.[45]  
Other splicing factors 
Other splicing factors have been also reported to be recurrently mutated in myeloid malignancies, 
although low frequencies of these mutations make their role in myeloid leukemogenesis being 
less established. These include an additional two components of splicing A complex (SF3A1 and 
U2AF2), PRPF40B, whose functions in RNA splicing is poorly defined[22], LUC7L2, a homologue 
of the putative RNA-binding protein Luc7, PRPF8 and other factors.[26, 32] LUC7L2 is thought to 
be involved in recognition of 5’ splice site and its inactivation mutations have been reported in 
MDS and secondary AML.[35, 46] PRPF8 (pre-mRNA processing factor 8) is a highly conserved 
component of both major and minor spliceosomes and its mutations also have been reported in 
de novo and secondary AML. [26, 35] Of note is that a recent study showed that truncating 
mutation of prpf8 impaired myeloid differentiation in Zebrafish, suggesting its essential role in 
hematopoietic development.[47] 
 
Clinical impact of spliceosome mutations 
  
Despite their common role in myeloid leukemogenesis anticipated from their non-overlapped 
distribution and functional implications, they seemed to have different impacts on clinical outcome 
in MDS and other myeloid malignancies. It seems that SF3B1 mutations are consistently 
associated with better overall survival (OS) and leukemia free survival (LFS) in MDS and RARS-
T,[23, 41] although initial reports showed conflicting observations.[42, 48]  
SRSF2 mutations are more common in advanced MDS subtypes (RAEB) and associated 
with a significantly shorter OS and LFS,[35, 49] while these mutations seemed to have no 
significant impact on prognosis among CMML patients.[50, 51] SRSF2-mutated AML transformed 
from MPN also have a shorter OS.[39] In addition, Lasho et al. and Vannucchi et al. reported 
SRSF2 mutations were associated with poor prognosis in primary myelofibrosis (PMF) 
patients.[52, 53] U2AF1 mutated MDS cases are associated with faster progression to secondary 
AML with no significant effects on OS or event free survivals[24],[54], whereas another group 
reported a significantly shorter OS for U2AF1 mutated myeloid malignancies.[35] ZRSR2 
mutations did not seem to affect prognosis.[55] The IPSS and the revised IPSS (IPSS-R) have 
been widely used for prognostication of MDS patients, however, this does not take into account 
for somatic mutations. Therefore, there are several attempts to integrate the mutational 
information of these genes into the prognostic model of MDS.[55, 56] 
On the other hand, SF3B1 mutations on CLL were associated with poor prognosis[31, 32, 
57] and more advanced fludarabine refractory disease.[33] Rossi et al. has proposed an 
integrated prognostic model of cytogenetic and molecular markers including SF3B1 
mutations.[58]  
 
Splicing factor mutations in solid cancers 
Splicing factor mutations also have been reported in a wide variety of solid cancers, although 
generally at much lower frequencies. SF3B1 has been reported to be mutated in less than 4% of 
breast cancer, endometrial cancer, bladder cancer, pancreatic ductal adenocarcinoma and 
adenoid cystic carcinoma, where mutations were distributed at the same hot spots as reported in 
MDS and CLL, such as K700E and K666Q.[23, 59-62] SF3B1 mutations were also common in 
uveral melanoma, in which most of the mutations almost exclusively involved R625.[63, 64] In 
uveal melanoma, the R625 mutations were associated with a lower metastasis rate and good 
prognosis, whereas those at other nucleotide positions were found in uveal melanomas with 
disomy 3 that developed metastases.[64] The U2AF1 S34F mutation was found in 3% of the 
cases with lung adenocarcinoma.[65]  
 
  
Splicing factor mutations and disease progression 
Deep sequencing of mutant alleles in cancer specimens provides a clue to speculate the origin of 
splicing factor mutations during clonal evolution.[24],[41] Thus, in the majority of cases with 
myeloid malignancies analyzed, SF3B1 and U2AF1 mutations generally showed a high allelic 
burden in both CD34-positive cell and granulocyte derived DNA, suggesting that these mutations 
were acquired during early development of multipotent hematopoietic stem cells and transmitted 
to their myeloid progenitors.[24],[41] Recent high-throughput targeted sequencing of 94-111 
genes in a large cohort of patients with MDS and related neoplasms also confirmed that splicing 
factor mutations were typically acquired early. [55, 56] Similarly, SRSF2 mutations, together with 
KIT D816V and TET2 mutations, also showed a high allelic burden in advanced systemic 
mastocytosis and could be early events.[40] Analysis of multiple mutations using single-cell-
derived colonies provides more direct information about the order of mutations, which clarified 
that SRSF2 mutation is thought to be one of the initiating mutations of CMML pathogenesis 
together with TET2 mutation according to their higher prevalence.[66]  
However, the founder role of the splicing factor mutation could be variable depending on 
cases. In the initial report in RARS-T, which is characterized by frequent coexisting mutations of 
SF3B1, and JAK2 and/or MPL, SF3B1 mutations showed higher allelic burden compared to 
coexisting JAK2/MPL mutations, suggesting that the JAK2 or MPL mutations occurred in a pre-
existing SF3B1-mutated cell.[41] In a recent report, in contrast, higher allelic burden of JAK2 than 
SF3B1 mutant alleles indicated that SF3B1 mutations in a pre-existing MPN clone having a JAK2 
mutation was implicated in the development of RARS-T.[67] Also, in the case of CLL, estimation 
of multiple driver mutations/chromosomal lesions using whole-exome sequencing and copy 
number analyses revealed that SF3B1 mutations represented subclonal lesions in an 
approximately half of the SF3B1-mutated CLL cases.[36] Similarly, U2AF1 mutations in HCLv 
were also thought to be subclonal mutations because of their lower allele frequencies.[37] 
 
Functional impacts of splicing factor mutations 
Despite strong genetic evidence of their involvement in clonal selection, the molecular mechanism 
of splicing factor mutations remains largely unknown. When overexpressed in HeLa cells, mutant 
U2AF1, but not the wild-type allele, induces severe suppression, rather than promotion, of cell 
proliferation with severe cell cycle arrest at G2/M transition and increased apoptosis.[22] Mutant 
U2AF1-transduced hematopoietic stem/progenitor cells show compromised repopulating 
capacity.[22] However, the interpretation of these observations may be complicated by the fact 
that transduction of oncogenic alleles potentially induces cellular stress that could result in cell 
  
senescence or induction of apoptosis.[68] While the hot-spot mutations always exists in 
heterozygous state, overexpression of these mutant alleles may rather mimic homozygous 
mutations in their expression level. Thus more sophisticated evaluation would be required to 
evaluate the oncogenic function of the splicing factor mutations, possibly using appropriate mouse 
model. On the other hand, some evidence suggested that other driver mutations or cytogenetic 
changes could contribute to the clonal dominance of cells with splicing factor mutations 
cooperatively. For example, in MDS, SRSF2 mutations frequently co-occurred with IDH2 [56] and 
TET2 mutations.[55] Similarly, in CLL, SF3B1 mutations were frequently co-occurred with 
del(11q).[31] 
Given the critical role of these splicing factors in pre-mRNA processing, one would speculate that 
their oncogenic actions are through de-regulated pre-mRNA splicing, leading to abnormal protein 
expression of relevant genes. In fact, when transduced in HeLa cells, the U2AF1 S34F mutant 
allele induces a variety of abnormal RNA splicing in a global manner, including exon skipping, 
unspliced intron, altered splice site recognition and altered exon usage ([22] and unpublished 
observation) (Figure 4). Abnormal exon skipping in mutant U2AF1-transduced cells was also 
demonstrated using a minigene reporter assay.[24] Of interest, an increased splicing activity was 
demonstrated for U2AF1 S34F mutant-transduced cells compared to wild-type U2AF1-
transduced cells in a double-reported splicing assay[24], supporting the putative gain of function 
of this allele. Visconte et al. performed knock-down experiment of SF3B1 gene on K562 cell line 
and showed dysfunction of splicing exclusively affected U2-type introns as expected.[69]  
Of note is mutations in ubiquitous spliceosome components actually cause specific phenotypes 
such as myelodysplasia and CLL. In this context, mutated splicesome components are ubiquitous 
but not necessarily essential for all introns or splice sites. For examples, AG-independent 3’ splice 
site which has a long stretch of pyrimidines can bind to U2AF2 without U2AF1.[70, 71] Therefore, 
one or more sensitive pre-mRNA to these mutations may cause such disease phenotypes. 
However, currently, little is known about the functionally relevant gene targets for abnormal 
splicing that would be caused by these mutations, if ever it play a major role in the development 
of MDS and other cancers. Przychodzen et al. analyzed RNA sequencing data of AML patients 
with and without U2AF1 mutation and identified U2AF1 mutant-specific splicing patterns, including 
exon skipping and exon retention in 35 genes, which are involved in functionally important 
pathways such as cell cycle and RNA processing.[72] Quesada et al. performed exon arrays and 
RNA sequencing of CLL samples with SF3B1 mutations and showed impaired RNA splicing 
activities of genes such as FOXP1, whose splicing variants are known to be associated with 
diffuse large B cell lymphoma (DLBCL).[32] However, the relevance of abnormal splicing of these 
  
genes to leukemogenesis has not been confirmed and needs further investigation in the future. 
Papaemmanuil et al. preformed expression analyses of CD34+ bone marrow cells derived from 
MDS patients and identified 94 genes which were down-regulated in SF3B1 mutated cases.[23] 
Among these, 7 of 50 most significantly down-regulated genes were related to mitochondrial 
functions, deregulation of which could be implicated in abnormal iron-metabolism that is a 
characteristic of RARS. Furney et al. performed RNA sequencing of uveal melanoma samples 
and revealed that SF3B1 mutations were associated with differential alternative splicing of ABCC5, 
UQCC and the long non-coding RNA (lncRNA) CRNDE.[73] 
Finally, abnormal pre-mRNA splicing may not be the only mechanism that explains the 
oncogenic capacity of these splicing factor mutations. Several lines of evidence indicate close 
coupling between transcription and pre-mRNA splicing[4], in which possible interactions between 
epigenetic regulators and the splicing machinery.[74, 75] In addition, close associations between 
mutation types and disease subtypes could be better explained by the discrete function of each 
mutation other than the common function in pre-mRNA splicing. For example, sf3b1 is localized 
on the 5’ region of the Hox gene cluster and physically interacts with different components in 
polycomb repressive complex 1 (PRC1), such as Zfp144 and Rnf2, which seem to be functionally 
relevant interactions. In fact, sf3b1+/− mice showed posterior transformation of vertebrae with 
abnormal Hox gene expression but not with abnormal splicing of the relevant Hox gene transcripts, 
which is repressed by the background of trithorax mutation (mll mutation).[76] It has been 
demonstrated that SRSF2 was also involved in the regulation of DNA stability and that depletion 
of SRSF2 can lead to genomic instability.[77] Of interest in this context, regardless of disease 
subtypes, samples with SRSF2 mutations were reported to have significantly more mutations of 
other genes compared with U2AF1 mutations.[22] 
 
Therapeutic implication of splicing factor mutations 
Given the essential role of pre-mRNA splicing in cell homeostasis, inhibition of splicing factors 
using low molecular weight compounds that targets mutated spliceosome components could be 
an interest of possible therapeutics, because cancer cells carrying these splicing factor mutations 
are likely to have compromised pre-mRNA splicing and could be more sensitive to these 
compounds than unmutated cells (synthetic lethality) (Figure 5).[78] Homozygous deletion of 
sf3b1 allele results in lethality in the very early step during development.[76] Several compounds 
have been known to inhibit pre-mRNA splicing. Spliceostatin A is the methylketal derivative of 
natural product FR901464, who has anti-cancer activity, and inhibit RNA splicing through the 
connection with SF3B complex.[79] E7107 is the derivative of natural product pladienolide B with 
  
anticancer effect and also inhibit RNA splicing through the binding with SAP130 (SF3B3).[80] In 
addition, Sudemycin,[81] which is the analog of FR901464, and Meayamycin,[82] that is totally 
synthesized FR901464 analog, are also shown to inhibit RNA splicing and show anticancer 
activity. Although currently, there is no proof of concept for this therapeutic possibility shown 
experimentally, it would be an intriguing possibility to be tested. 
 
CONCLUDING REMARKS 
Splicing factors represent a novel class of mutational targets in cancer, especially in MDS and 
other hematopoietic malignances, which were unexpectedly revealed by massively parallel 
sequencing of cancer genome. Most of these mutations involved the spliceosome components 
involved in the 3’ splice site recognition during early steps of RNA splicing, including SF3B1, 
U2AF1, SRSF2 and ZRSR2, indicating their oncogenic actions through de-regulated RNA splicing, 
although the exact mechanism of their oncogenic actions is largely unknown. A potential role of 
spliceosome inhibition in novel therapeutics for these intractable neoplasms is also an interest of 




Table 1 Splicing factor mutations identified in various types of cancers 
Gene Disease type Frequency Citation 
SF3B1 
MDS, CMML, AML 
82.6%(RARS), 76.0%(RCMD-
RS), 6.5%(MDS without RS), 
4.5%(CMML), 
4.8%(AML/MDS), 2.6%(AML) 






Papaemmanuil E, et al. 
NEJM, 2011[23] 
MDS(RARS, RCMD-
RS), MDS/MPN 64%(RARS), 72%(RARS-T) 






Malcovati L, et al. Blood, 
2011[41] 
MDS 73%(RARS), 37%(RCMD-RS), 18%(RAEB1-RS) 
Patnaik MM, et al. Blood, 
2011[42] 
MDS 14.8% Damm F, et al. Leukemia, 2011[48] 
RARS, RCMD-RS 60.0% Makishima H, et al. Blood, 2012[35] 
MDS 16.4% Damm F, et al. Blood, 2012[45] 
Lower-risk MDS 22.0% Bejar R, et al. JCO, 2012[83] 
MDS, secondary AML 7.0% Walter MJ, et al. Leukemia, 2013[84] 
MDS 16.0% Mian SA, et al. Haematologica, 2013[85]  
MDS, MDS/MPN 24% Papaemmanuil E, et al. Blood, 2013[56] 
MDS, MDS/MPN 32.9% Haferlach T, et al. Leukemia 2013[55] 
CMML 6.0% Patnaik MM, et al. Am J Hematol, 2013[51] 
CMML 6.0% Itzykson R, et al. JCO, 2013[86] 
RARS-T 84.8% Broséus J, et al. Leukemia, 2013[43] 
MPN 2.0% Nangalia J, et al. NEJM, 2013[27] 
PMF 6.5% Lasho TL, et al. Leukemia, 2011[87] 
Secondary AML 
derived from MPNs 3.8% 
Zhang SJ, et al. Blood, 
2012[39] 
de novo AML 0.5% TCGA. NEJM, 2013[26] 
CLL 15.0% Wang L, et al. NEJM, 2011[31] 
CLL 9.7% Quesada V, et al. Nat Gent, 2012[32] 
Fludarabine-
refractory CLL 17.0% 
Rossi D, et al. Blood, 
2011[33] 
  
Breast cancer 4.0% Stephens PJ, et al. Nature, 2012[59] 
Breast cancer 3.9% Ellis ML, et al. Nature, 2012[60] 
Pancreatic ductal 
adenocarcinoma 4.0% ICGC. Nature, 2012[61] 
Uveral melanoma 19.0% Harbour J, et al. Nat Gent, 2012[63] 
U2AF1 
MDS, CMML, AML 
11.6%(MDS without RS), 
8%(CMML), 9.7%(AML/MDS), 
1.3%(AML) 
Yoshida K, et al. Nature, 
2011[22] 
MDS, CMML 8.7% Graubert T, et al. Nat Gent, 2011[24] 
MDS, CMML, AML 
6%(Low-risk MDS), 11%(High-
risk MDS), 17%(CMML), 
9%(AML) 
Makishima H, et al. Blood, 
2012[35] 
Lower-risk MDS 16.0% Bejar R, et al. JCO, 2012[83] 
MDS 5.4% Damm F, et al. Blood, 2012[45] 
MDS 7.3% Thol F, et al. Blood, 2012[54] 
MDS, secondary AML 10.2% Walter MJ, et al. Leukemia, 2013[84] 
MDS 10.0% Mian SA, et al. Haematologica, 2013[85] 
MDS, MDS/MPN 6.1% Papaemmanuil E, et al. Blood, 2013[56] 
MDS, MDS/MPN 7.7% Haferlach T, et al. Leukemia 2013[55] 
CMML 9.0% Patnaik MM, et al. Am J Hematol, 2013[51] 
CMML 5.0% Itzykson R, et al. JCO, 2013[86] 
MPN 2.6% Nangalia J, et al. NEJM, 2013[27] 
Therapy-related MDS 
and AML 2.6% 
Shih AH, et al. 
Haematologica, 2013[88] 
Secondary AML 
derived from MPNs 5.7% 
Zhang SJ, et al. Blood, 
2012[39] 
de novo AML 4.0% TCGA. NEJM, 2013[26] 
Advanced systemic 
mastocytosis 5.6% 




Hirabayashi S, et al. Blood, 
2012[28] 
JMML 3.7% Takita J, et al. Leukemia, 2012[29] 
Lung 
adenocarcinoma 3.0% 




MDS, CMML, MPN 
 28.4%(CMML), 11.6%(MDS 
without RS), 5.5%(RARS, 
RCMD-RS), 6.5%(AML/MDS), 
0.7%(AML), 1.9%(MPN) 
Yoshida K, et al. Nature, 
2011[22] 
MDS, CMML 28%(CMML) Makishima H, et al. Blood, 2012[35] 
Lower-risk MDS 13.0% Bejar R, et al. JCO, 2012[83] 
MDS 11.1% Damm F, et al. Blood, 2012[45] 
MDS 12.4% Thol F, et al. Blood, 2012[54] 
MDS 14.6% Wu SJ, et al. Blood, 2012[49] 
MDS 13.0% Mian SA, et al. Haematologica, 2013[85] 
MDS, MDS/MPN 14% Papaemmanuil E, et al. Blood, 2013[56] 
MDS, MDS/MPN 17.5% Haferlach T, et al. Leukemia 2013[55] 
CMML 47.0% Meqqendorfer M, et al. Blood, 2012[50] 
CMML 40.0% Patnaik MM, et al. Am J Hematol, 2013[51] 
MPN 1.3% Nangalia J, et al. NEJM, 2013[27] 
PMF 17.0% Lasho TL, et al. Blood, 2012[52] 
PMF 8.5% Vannucchi AM, et al. Leukemia 2013[53] 
Secondary AML 
derived from MPNs 18.9% 
Zhang SJ, et al. Blood, 
2012[39] 
Therapy-related MDS 
and AML 7.9% 
Shih AH, et al. 
Haematologica, 2013[88] 
de novo AML 0.5% TCGA. NEJM, 2013[26] 
Advanced systemic 
mastocytosis 35.9% 




Hirabayashi S, et al. Blood, 
2012[28] 
JMML 3.7% Takita J, et al. Leukemia, 2012[29] 
ZRSR2 
MDS, CMML 
8%(CMML), 7.7%(MDS without 
RS), 1.4%(RARS, RCMD-RS), 
1.6%(AML/MDS), 1.9%(MPN) 
Yoshida K, et al. Nature, 
2011[22] 
MDS, CMML 0.8% Makishima H, et al. Blood, 2012[35] 
MDS 11.1% Damm F, et al. Blood, 2012[45] 
MDS 3.1% Thol F, et al. Blood, 2012[54] 
  
MDS, secondary AML 2.5% Walter MJ, et al. Leukemia, 2013[84] 
MDS 1.0% Mian SA, et al. Haematologica, 2013[85] 
MDS, MDS/MPN 4.5% Papaemmanuil E, et al. Blood, 2013[56] 
MDS, MDS/MPN 7.6% Haferlach T, et al. Leukemia 2013[55] 
CMML 8.0% Itzykson R, et al. JCO, 2013[86] 
Secondary AML 
derived from MPNs 1.9% 
Zhang SJ, et al. Blood, 
2012[39] 
SF3A1 MDS, CMML, AML 1.2% Yoshida K, et al. Nature, 2011[22] 
PRPF40B MDS, CMML, AML 1.2% Yoshida K, et al. Nature, 2011[22] 
U2AF2 
MDS, CMML, AML 0.7% Yoshida K, et al. Nature, 2011[22] 
de novo AML 0.5% TCGA. NEJM, 2013[26] 
CLL 1.9% Quesada V, et al. Nat Gent, 2012[32]  
SF1 MDS, CMML, AML 0.9% Yoshida K, et al. Nature, 2011[22] 
LUC7L2 
MDS, CMML 0.8% Makishima H, et al. Blood, 2012[35] 
MDS, secondary AML 0.6% Walter MJ, et al. Leukemia, 2013[84] 
PRPF8 MDS, CMML 0.8% 
Makishima H, et al. Blood, 
2012[35] 
de novo AML 2.0% TCGA. NEJM, 2013[26] 
SNRNP200 MDS, secondary AML 0.6% 
Walter MJ, et al. 
Leukemia, 2013[84] 
de novo AML 0.5% TCGA. NEJM, 2013[26] 
CSTF2T de novo AML 0.5% TCGA. NEJM, 2013[26] 
DDX1 de novo AML 0.5% TCGA. NEJM, 2013[26] 
DDX23 de novo AML 0.5% TCGA. NEJM, 2013[26] 
DHX32 de novo AML 0.5% TCGA. NEJM, 2013[26] 
HNRNPK de novo AML 0.5% TCGA. NEJM, 2013[26] 
METTL3 de novo AML 0.5% TCGA. NEJM, 2013[26] 
PLRG1 de novo AML 0.5% TCGA. NEJM, 2013[26] 
POLR2A de novo AML 0.5% TCGA. NEJM, 2013[26] 
PRPF3 de novo AML 0.5% TCGA. NEJM, 2013[26] 
RBMX de novo AML 0.5% TCGA. NEJM, 2013[26] 
SRRM2 de novo AML 0.5% TCGA. NEJM, 2013[26] 
SRSF2 de novo AML 0.5% TCGA. NEJM, 2013[26] 
SRSF6 de novo AML 0.5% TCGA. NEJM, 2013[26] 
SUPT5H de novo AML 0.5% TCGA. NEJM, 2013[26] 
TRA2B de novo AML 0.5% TCGA. NEJM, 2013[26] 
  
U2AF1L4 de novo AML 0.5% TCGA. NEJM, 2013[26] 
CELF4 CLL 1.9% Quesada V, et al. Nat Gent, 2012[32]  
SFRS1 CLL 1.9% Quesada V, et al. Nat Gent, 2012[32]  
SFRS7 CLL 1.0% Quesada V, et al. Nat Gent, 2012[32] 
 






Pre-mRNA and major spliceosomes 
The U1, U2, U4/U6, U5 snRNPs are the main components of the major spliceosomes and each 
snRNP consists of a small nuclear RNA (snRNA) and a varying number of associated proteins. 
Assembly of spliceosomes begins with binding of U1 snRNP to the 5’ splice site of intron. 
Subsequently, U2 snRNP interacts with the BPS (A complex) and then U4/U6.U5 tri-snRNP are 
recruited, forming the B complex. After the release of U1 and U4 snRNP, activated B complex 
undergo the catalytic process of splicing (C complex). Catalytic process of pre-mRNA splicing is 
a two-step process, during which splicesomes are assembled in a stepwise fashion as splicing 
proceeds.[1, 2] In the first step, the 5' splice site is cleaved and the 5' residue of the intron is linked 
to near the 3' splice junction. In the second step, the 3' splice site is cleaved, producing ligated 




Frequent splicing factor mutations in myelodysplasia 
Most of the mutations affected the components that are involved in the initial steps of pre-mRNA 
splicing including 5’-splice site recognition (LUC7L2) and 3’-splice site recognition (SF3B1, 
SRSF2, U2AF1, ZRSR2, U2AF2, SF3A1 and SF1) (upper panel). These mutations are almost 
mutually exclusive, suggesting a common impact of these mutations on RNA splicing in the 
pathogenesis of myelodysplasia. Distribution of mutations in 8 spliceosome genes, where 
diagnosis of each sample is shown by indicated colors (lower panel). 
W: Trp residues, RRM: RNA-recognition motif, UHM: U2AF homology motif domain, RS domain: 
arginine and serine rich domain 
 
Figure 3 
Reported mutations of splicing factor genes including U2AF1, SRSF2, ZRSR2 and SF3B1 
in myelodysplasia 
Mutations of U2AF1, SRSF2 and SF3B1 clustered in several hot spots (S34 and Q157 of U2AF1; 
P95 of SRSF2; E622, R625, H662, K666 and K700 of SF3B1), suggesting the gain-of-function 
nature of these mutations. On the other hand, ZRSR2 mutations were widely distributed along 
the entire coding region and most of them were nonsense mutations or frameshift changes, or 
involved splicing donor/acceptor sites that caused either a premature truncation or a large 
structural change of the protein, leading to loss-of-function. 
Zn: Zinc finger domain, UHM: U2AF homology motif domain, RRM: RNA recognition motif domain, 
HD: HEAT domain 
 
Figure 4 
A variety of splicing alterations observed in mutant U2AF1-transduced HeLa cells 
U2AF1 S34F mutant allele induces a variety of abnormal RNA splicing in a global manner, 
including exon skipping, unspliced intron, altered splice site recognition and altered exon usage. 
 
Figure 5 
Potential of splicing factor mutations as therapeutic targets (synthetic lethality) 
Cancer cells carrying splicing factor mutations (lower panel) are likely to have compromised pre-











1. Wahl MC, Will CL, Luhrmann R: The spliceosome: design principles of a dynamic 
RNP machine. Cell 2009, 136:701-718. 
2. Kornblihtt AR, Schor IE, Allo M, Dujardin G, Petrillo E, Munoz MJ: Alternative splicing: 
a pivotal step between eukaryotic transcription and translation. Nat Rev Mol Cell Biol 
2013, 14:153-165. 
3. Turunen JJ, Niemela EH, Verma B, Frilander MJ: The significant other: splicing by the 
minor spliceosome. Wiley Interdiscip Rev RNA 2013, 4:61-76. 
4. Lin S, Coutinho-Mansfield G, Wang D, Pandit S, Fu XD: The splicing factor SC35 has 
an active role in transcriptional elongation. Nat Struct Mol Biol 2008, 15:819-826. 
5. Maciejewski JP, Padgett RA: Defects in spliceosomal machinery: a new pathway of 
leukaemogenesis. Br J Haematol 2012, 158:165-173. 
6. Cazzola M, Rossi M, Malcovati L: Biologic and clinical significance of somatic 
mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood 2013, 121:260-269. 
7. Wan Y, Wu CJ: SF3B1 mutations in chronic lymphocytic leukemia. Blood 2013, 
121:4627-4634. 
8. Wang GS, Cooper TA: Splicing in disease: disruption of the splicing code and the 
decoding machinery. Nat Rev Genet 2007, 8:749-761. 
9. Cartegni L, Chew SL, Krainer AR: Listening to silence and understanding nonsense: 
exonic mutations that affect splicing. Nat Rev Genet 2002, 3:285-298. 
10. Cooper TA, Wan L, Dreyfuss G: RNA and disease. Cell 2009, 136:777-793. 
11. Bernier FP, Caluseriu O, Ng S, Schwartzentruber J, Buckingham KJ, Innes AM, Jabs EW, 
Innis JW, Schuette JL, Gorski JL, et al: Haploinsufficiency of SF3B4, a component of 
the pre-mRNA spliceosomal complex, causes Nager syndrome. Am J Hum Genet 
2012, 90:925-933. 
12. Edery P, Marcaillou C, Sahbatou M, Labalme A, Chastang J, Touraine R, Tubacher E, 
Senni F, Bober MB, Nampoothiri S, et al: Association of TALS developmental disorder 
with defect in minor splicing component U4atac snRNA. Science 2011, 332:240-243. 
13. He H, Liyanarachchi S, Akagi K, Nagy R, Li J, Dietrich RC, Li W, Sebastian N, Wen B, Xin 
B, et al: Mutations in U4atac snRNA, a component of the minor spliceosome, in the 
developmental disorder MOPD I. Science 2011, 332:238-240. 
14. Mordes D, Yuan L, Xu L, Kawada M, Molday RS, Wu JY: Identification of photoreceptor 
genes affected by PRPF31 mutations associated with autosomal dominant retinitis 
pigmentosa. Neurobiol Dis 2007, 26:291-300. 
15. David CJ, Manley JL: Alternative pre-mRNA splicing regulation in cancer: pathways 
and programs unhinged. Genes Dev 2010, 24:2343-2364. 
16. Kim E, Goren A, Ast G: Insights into the connection between cancer and alternative 
splicing. Trends Genet 2008, 24:7-10. 
17. Xerri L, Hassoun J, Devilard E, Birnbaum D, Birg F: BCL-X and the apoptotic machinery 
of lymphoma cells. Leuk Lymphoma 1998, 28:451-458. 
18. Fushimi K, Ray P, Kar A, Wang L, Sutherland LC, Wu JY: Up-regulation of the 
proapoptotic caspase 2 splicing isoform by a candidate tumor suppressor, RBM5. 
Proc Natl Acad Sci U S A 2008, 105:15708-15713. 
19. Sheen-Chen SM, Chen HS, Eng HL, Chen WJ: Circulating soluble Fas in patients with 
breast cancer. World J Surg 2003, 27:10-13. 
20. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR: The gene encoding the 
splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 2007, 14:185-193. 
21. Tefferi A, Vardiman JW: Myelodysplastic syndromes. N Engl J Med 2009, 361:1872-
1885. 
  
22. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, Sato Y, Sato-
Otsubo A, Kon A, Nagasaki M, et al: Frequent pathway mutations of splicing 
machinery in myelodysplasia. Nature 2011, 478:64-69. 
23. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, Pellagatti A, 
Wainscoat JS, Hellstrom-Lindberg E, Gambacorti-Passerini C, et al: Somatic SF3B1 
mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011, 365:1384-
1395. 
24. Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J, Krysiak K, Harris CC, 
Koboldt DC, Larson DE, et al: Recurrent mutations in the U2AF1 splicing factor in 
myelodysplastic syndromes. Nat Genet 2011, 44:53-57. 
25. Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, Jerez A, O'Keefe C, Rogers 
HJ, Sekeres MA, Maciejewski JP, Tiu RV: SF3B1, a splicing factor is frequently 
mutated in refractory anemia with ring sideroblasts. Leukemia 2011, 26:542-545. 
26. TCGA: Genomic and epigenomic landscapes of adult de novo acute myeloid 
leukemia. N Engl J Med 2013, 368:2059-2074. 
27. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, 
Kollmann K, Kent DG, et al: Somatic CALR mutations in myeloproliferative 
neoplasms with nonmutated JAK2. N Engl J Med 2013, 369:2391-2405. 
28. Hirabayashi S, Flotho C, Moetter J, Heuser M, Hasle H, Gruhn B, Klingebiel T, Thol F, 
Schlegelberger B, Baumann I, et al: Spliceosomal gene aberrations are rare, coexist 
with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS 
and JMML. Blood 2012, 119:e96-99. 
29. Takita J, Yoshida K, Sanada M, Nishimura R, Okubo J, Motomura A, Hiwatari M, Oki K, 
Igarashi T, Hayashi Y, Ogawa S: Novel splicing-factor mutations in juvenile 
myelomonocytic leukemia. Leukemia 2012, 26:1879-1881. 
30. Je EM, Yoo NJ, Kim YJ, Kim MS, Lee SH: Mutational analysis of splicing machinery 
genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors. Int 
J Cancer 2013, 133:260-265. 
31. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, Werner L, 
Sivachenko A, DeLuca DS, Zhang L, et al: SF3B1 and other novel cancer genes in 
chronic lymphocytic leukemia. N Engl J Med 2011, 365:2497-2506. 
32. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L, Ramsay AJ, 
Bea S, Pinyol M, Martinez-Trillos A, et al: Exome sequencing identifies recurrent 
mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat 
Genet 2011, 44:47-52. 
33. Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M, Fangazio M, Vaisitti 
T, Monti S, Chiaretti S, et al: Mutations of the SF3B1 splicing factor in chronic 
lymphocytic leukemia: association with progression and fludarabine-refractoriness. 
Blood 2011, 118:6904-6908. 
34. Ramsay AJ, Rodriguez D, Villamor N, Kwarciak A, Tejedor JR, Valcarcel J, Lopez-
Guillermo A, Martinez-Trillos A, Puente XS, Campo E, et al: Frequent somatic mutations 
in components of the RNA processing machinery in chronic lymphocytic leukemia. 
Leukemia 2013, 27:1600-1603. 
35. Makishima H, Visconte V, Sakaguchi H, Jankowska AM, Abu Kar S, Jerez A, Przychodzen 
B, Bupathi M, Guinta K, Afable MG, et al: Mutations in the spliceosome machinery, a 
novel and ubiquitous pathway in leukemogenesis. Blood 2012, 119:3203-3210. 
36. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, 
Stewart C, Sivachenko A, Wang L, et al: Evolution and impact of subclonal mutations 
in chronic lymphocytic leukemia. Cell 2013, 152:714-726. 
  
37. Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, Abaan OD, Davis SR, 
Kreitman RJ, Meltzer PS: High prevalence of MAP2K1 mutations in variant and 
IGHV4-34-expressing hairy-cell leukemias. Nat Genet 2014, 46:8-10. 
38. Chen M, Manley JL: Mechanisms of alternative splicing regulation: insights from 
molecular and genomics approaches. Nat Rev Mol Cell Biol 2009, 10:741-754. 
39. Zhang SJ, Rampal R, Manshouri T, Patel J, Mensah N, Kayserian A, Hricik T, Heguy A, 
Hedvat C, Gonen M, et al: Genetic analysis of patients with leukemic transformation 
of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are 
associated with adverse outcome. Blood 2012, 119:4480-4485. 
40. Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, Kohlmann A, 
Grossmann V, Meggendorfer M, Horny HP, et al: Comprehensive mutational profiling 
in advanced systemic mastocytosis. Blood 2013, 122:2460-2466. 
41. Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, 
Travaglino E, Groves MJ, Godfrey AL, Ambaglio I, et al: Clinical significance of SF3B1 
mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative 
neoplasms. Blood 2011, 118:6239-6246. 
42. Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G, 
Steensma DP, Pardanani A, Hanson CA, Tefferi A: SF3B1 mutations are prevalent in 
myelodysplastic syndromes with ring sideroblasts but do not hold independent 
prognostic value. Blood 2011, 119:569-572. 
43. Broseus J, Alpermann T, Wulfert M, Florensa Brichs L, Jeromin S, Lippert E, Rozman M, 
Lifermann F, Grossmann V, Haferlach T, et al: Age, JAK2 and SF3B1 mutations are the 
main predicting factors for survival in refractory anaemia with ring sideroblasts and 
marked thrombocytosis. Leukemia 2013, 27:1826-1831. 
44. Shen H, Zheng X, Luecke S, Green MR: The U2AF35-related protein Urp contacts the 
3' splice site to promote U12-type intron splicing and the second step of U2-type 
intron splicing. Genes Dev 2010, 24:2389-2394. 
45. Damm F, Kosmider O, Gelsi-Boyer V, Renneville A, Carbuccia N, Hidalgo-Curtis C, Della 
Valle V, Couronne L, Scourzic L, Chesnais V, et al: Mutations affecting mRNA splicing 
define distinct clinical phenotypes and correlate with patient outcome in 
myelodysplastic syndromes. Blood 2012, 119:3211-3218. 
46. Singh H, Lane AA, Correll M, Przychodzen B, Sykes DB, Stone RM, Ballen KK, Amrein 
PC, Maciejewski J, Attar EC: Putative RNA-splicing gene LUC7L2 on 7q34 represents 
a candidate gene in pathogenesis of myeloid malignancies. Blood Cancer J 2013, 
3:e117. 
47. Keightley MC, Crowhurst MO, Layton JE, Beilharz T, Markmiller S, Varma S, Hogan BM, 
de Jong-Curtain TA, Heath JK, Lieschke GJ: In vivo mutation of pre-mRNA processing 
factor 8 (Prpf8) affects transcript splicing, cell survival and myeloid differentiation. 
FEBS Lett 2013, 587:2150-2157. 
48. Damm F, Thol F, Kosmider O, Kade S, Loffeld P, Dreyfus F, Stamatoullas-Bastard A, 
Tanguy-Schmidt A, Beyne-Rauzy O, de Botton S, et al: SF3B1 mutations in 
myelodysplastic syndromes: clinical associations and prognostic implications. 
Leukemia 2011, 26:1137-1140. 
49. Wu SJ, Kuo YY, Hou HA, Li LY, Tseng MH, Huang CF, Lee FY, Liu MC, Liu CW, Lin CT, 
et al: The clinical implication of SRSF2 mutation in patients with myelodysplastic 
syndrome and its stability during disease evolution. Blood 2012, 120:3106-3111. 
50. Meggendorfer M, Roller A, Haferlach T, Eder C, Dicker F, Grossmann V, Kohlmann A, 
Alpermann T, Yoshida K, Ogawa S, et al: SRSF2 mutations in 275 cases with chronic 
myelomonocytic leukemia (CMML). Blood 2012, 120:3080-3088. 
51. Patnaik MM, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA, Ketterling 
RP, Pardanani A, Tefferi A: Spliceosome mutations involving SRSF2, SF3B1, and 
  
U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and 
prognostic relevance. Am J Hematol 2013, 88:201-206. 
52. Lasho TL, Jimma T, Finke CM, Patnaik M, Hanson CA, Ketterling RP, Pardanani A, Tefferi 
A: SRSF2 mutations in primary myelofibrosis: significant clustering with IDH 
mutations and independent association with inferior overall and leukemia-free 
survival. Blood 2012, 120:4168-4171. 
53. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, Finke C, 
Score J, Gangat N, Mannarelli C, et al: Mutations and prognosis in primary 
myelofibrosis. Leukemia 2013, 27:1861-1869. 
54. Thol F, Kade S, Schlarmann C, Loffeld P, Morgan M, Krauter J, Wlodarski MW, Kolking 
B, Wichmann M, Gorlich K, et al: Frequency and prognostic impact of mutations in 
SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012, 
119:3578-3584. 
55. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, Schnittger S, 
Sanada M, Kon A, Alpermann T, et al: Landscape of Genetic Lesions in 944 Patients 
with Myelodysplastic Syndromes. Leukemia 2013 [epub ahead of print]. 
56. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, Yoon CJ, 
Ellis P, Wedge DC, Pellagatti A, et al: Clinical and biological implications of driver 
mutations in myelodysplastic syndromes. Blood 2013, 122:3616-3627. 
57. Oscier DG, Rose-Zerilli MJ, Winkelmann N, Gonzalez de Castro D, Gomez B, Forster J, 
Parker H, Parker A, Gardiner A, Collins A, et al: The clinical significance of NOTCH1 
and SF3B1 mutations in the UK LRF CLL4 trial. Blood 2013, 121:468-475. 
58. Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Ciardullo C, Deambrogi C, Khiabanian 
H, Serra R, Bertoni F, et al: Integrated mutational and cytogenetic analysis identifies 
new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013, 121:1403-
1412. 
59. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, 
Martin S, Varela I, Bignell GR, et al: The landscape of cancer genes and mutational 
processes in breast cancer. Nature 2012, 486:400-404. 
60. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, 
Goldstein TC, et al: Whole-genome analysis informs breast cancer response to 
aromatase inhibition. Nature 2012, 486:353-360. 
61. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, 
Wilson PJ, Patch AM, Wu J, et al: Pancreatic cancer genomes reveal aberrations in 
axon guidance pathway genes. Nature 2012, 491:399-405. 
62. Stephens PJ, Davies HR, Mitani Y, Van Loo P, Shlien A, Tarpey PS, Papaemmanuil E, 
Cheverton A, Bignell GR, Butler AP, et al: Whole exome sequencing of adenoid cystic 
carcinoma. J Clin Invest 2013, 123:2965-2968. 
63. Harbour JW, Roberson ED, Anbunathan H, Onken MD, Worley LA, Bowcock AM: 
Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. 
Nat Genet 2013, 45:133-135. 
64. Martin M, Masshofer L, Temming P, Rahmann S, Metz C, Bornfeld N, van de Nes J, Klein-
Hitpass L, Hinnebusch AG, Horsthemke B, et al: Exome sequencing identifies 
recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 
3. Nat Genet 2013, 45:933-936. 
65. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, 
Capelletti M, Sivachenko A, et al: Mapping the hallmarks of lung adenocarcinoma with 
massively parallel sequencing. Cell 2012, 150:1107-1120. 
66. Itzykson R, Kosmider O, Renneville A, Morabito M, Preudhomme C, Berthon C, Ades L, 
Fenaux P, Platzbecker U, Gagey O, et al: Clonal architecture of chronic 
myelomonocytic leukemias. Blood 2013, 121:2186-2198. 
  
67. Jeromin S, Haferlach T, Grossmann V, Alpermann T, Kowarsch A, Haferlach C, Kern W, 
Schnittger S: High frequencies of SF3B1 and JAK2 mutations in refractory anemia 
with ring sideroblasts associated with marked thrombocytosis strengthen the 
assignment to the category of myelodysplastic/myeloproliferative neoplasms. 
Haematologica 2013, 98:e15-17. 
68. McDuff FK, Turner SD: Jailbreak: oncogene-induced senescence and its evasion. 
Cell Signal 2011, 23:6-13. 
69. Visconte V, Rogers HJ, Singh J, Barnard J, Bupathi M, Traina F, McMahon J, Makishima 
H, Szpurka H, Jankowska A, et al: SF3B1 haploinsufficiency leads to formation of ring 
sideroblasts in myelodysplastic syndromes. Blood 2012, 120:3173-3186. 
70. Guth S, Martinez C, Gaur RK, Valcarcel J: Evidence for substrate-specific requirement 
of the splicing factor U2AF(35) and for its function after polypyrimidine tract 
recognition by U2AF(65). Mol Cell Biol 1999, 19:8263-8271. 
71. Pacheco TR, Coelho MB, Desterro JM, Mollet I, Carmo-Fonseca M: In vivo requirement 
of the small subunit of U2AF for recognition of a weak 3' splice site. Mol Cell Biol 
2006, 26:8183-8190. 
72. Przychodzen B, Jerez A, Guinta K, Sekeres MA, Padgett R, Maciejewski JP, Makishima 
H: Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. 
Blood 2013, 122:999-1006. 
73. Furney SJ, Pedersen M, Gentien D, Dumont AG, Rapinat A, Desjardins L, Turajlic S, 
Piperno-Neumann S, de la Grange P, Roman-Roman S, et al: SF3B1 mutations are 
associated with alternative splicing in uveal melanoma. Cancer Discov 2013, 3:1122-
1129. 
74. Allo M, Schor IE, Munoz MJ, de la Mata M, Agirre E, Valcarcel J, Eyras E, Kornblihtt AR: 
Chromatin and alternative splicing. Cold Spring Harb Symp Quant Biol 2010, 75:103-
111. 
75. Luco RF, Allo M, Schor IE, Kornblihtt AR, Misteli T: Epigenetics in alternative pre-mRNA 
splicing. Cell 2011, 144:16-26. 
76. Isono K, Mizutani-Koseki Y, Komori T, Schmidt-Zachmann MS, Koseki H: Mammalian 
polycomb-mediated repression of Hox genes requires the essential spliceosomal 
protein Sf3b1. Genes Dev 2005, 19:536-541. 
77. Xiao R, Sun Y, Ding JH, Lin S, Rose DW, Rosenfeld MG, Fu XD, Li X: Splicing regulator 
SC35 is essential for genomic stability and cell proliferation during mammalian 
organogenesis. Mol Cell Biol 2007, 27:5393-5402. 
78. Shaheen M, Allen C, Nickoloff JA, Hromas R: Synthetic lethality: exploiting the 
addiction of cancer to DNA repair. Blood 2011, 117:6074-6082. 
79. Kaida D, Motoyoshi H, Tashiro E, Nojima T, Hagiwara M, Ishigami K, Watanabe H, 
Kitahara T, Yoshida T, Nakajima H, et al: Spliceostatin A targets SF3b and inhibits 
both splicing and nuclear retention of pre-mRNA. Nat Chem Biol 2007, 3:576-583. 
80. Kotake Y, Sagane K, Owa T, Mimori-Kiyosue Y, Shimizu H, Uesugi M, Ishihama Y, Iwata 
M, Mizui Y: Splicing factor SF3b as a target of the antitumor natural product 
pladienolide. Nat Chem Biol 2007, 3:570-575. 
81. Fan L, Lagisetti C, Edwards CC, Webb TR, Potter PM: Sudemycins, novel small 
molecule analogues of FR901464, induce alternative gene splicing. ACS Chem Biol 
2011, 6:582-589. 
82. Albert BJ, McPherson PA, O'Brien K, Czaicki NL, Destefino V, Osman S, Li M, Day BW, 
Grabowski PJ, Moore MJ, et al: Meayamycin inhibits pre-messenger RNA splicing and 
exhibits picomolar activity against multidrug-resistant cells. Mol Cancer Ther 2009, 
8:2308-2318. 
83. Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, Raza A, 
Kantarjian H, Levine RL, Neuberg D, et al: Validation of a prognostic model and the 
  
impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin 
Oncol 2012, 30:3376-3382. 
84. Walter MJ, Shen D, Shao J, Ding L, White BS, Kandoth C, Miller CA, Niu B, McLellan MD, 
Dees ND, et al: Clonal diversity of recurrently mutated genes in myelodysplastic 
syndromes. Leukemia 2013, 27:1275-1282. 
85. Mian SA, Smith AE, Kulasekararaj AG, Kizilors A, Mohamedali AM, Lea NC, Mitsopoulos 
K, Ford K, Nasser E, Seidl T, Mufti GJ: Spliceosome mutations exhibit specific 
associations with epigenetic modifiers and proto-oncogenes mutated in 
myelodysplastic syndrome. Haematologica 2013, 98:1058-1066. 
86. Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, 
Berthon C, Ades L, Fenaux P, Beyne-Rauzy O, et al: Prognostic score including gene 
mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013, 31:2428-2436. 
87. Lasho TL, Finke CM, Hanson CA, Jimma T, Knudson RA, Ketterling RP, Pardanani A, 
Tefferi A: SF3B1 mutations in primary myelofibrosis: clinical, histopathology and 
genetic correlates among 155 patients. Leukemia 2011, 26:1135-1137. 
88. Shih AH, Chung SS, Dolezal EK, Zhang SJ, Abdel-Wahab OI, Park CY, Nimer SD, Levine 
RL, Klimek VM: Mutational analysis of therapy-related myelodysplastic syndromes 
and acute myelogenous leukemia. Haematologica 2013, 98:908-912. 
 
 
